Anthony J. Japour

4.6k total citations · 1 hit paper
34 papers, 3.2k citations indexed

About

Anthony J. Japour is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Anthony J. Japour has authored 34 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Infectious Diseases, 29 papers in Virology and 3 papers in Epidemiology. Recurrent topics in Anthony J. Japour's work include HIV Research and Treatment (29 papers), HIV/AIDS drug development and treatment (29 papers) and HIV/AIDS Research and Interventions (21 papers). Anthony J. Japour is often cited by papers focused on HIV Research and Treatment (29 papers), HIV/AIDS drug development and treatment (29 papers) and HIV/AIDS Research and Interventions (21 papers). Anthony J. Japour collaborates with scholars based in United States, United Kingdom and Netherlands. Anthony J. Japour's co-authors include Eugene Sun, Martin King, Barry Bernstein, Scott Brun, J. Brooks Jackson, Susan A. Fiscus, Yi Xu, Richard C. Reichman, Dale J. Kempf and José Ramón Arribas and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Anthony J. Japour

34 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection

2002 518 citations Sharon Walmsley, Barry Bernstein et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Anthony J. Japour

Since Specialization

Citations

This map shows the geographic impact of Anthony J. Japour's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anthony J. Japour with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anthony J. Japour more than expected).

Fields of papers citing papers by Anthony J. Japour

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anthony J. Japour. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anthony J. Japour. The network helps show where Anthony J. Japour may publish in the future.

Co-authorship network of co-authors of Anthony J. Japour

This figure shows the co-authorship network connecting the top 25 collaborators of Anthony J. Japour. A scholar is included among the top collaborators of Anthony J. Japour based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anthony J. Japour. Anthony J. Japour is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Transplanting islet cells can fix brittle diabetes. Why isn't it available in the U.S.? 2019 ·SHILAP Revista de lepidopterología ·Camillo Ricordi, Anthony J. Japour	5
2	Incidence of Myocardial Infarction in Randomized Clinical Trials of Protease Inhibitor-Based Antiretroviral Therapy: An Analysis of Four Different Protease Inhibitors 2003 ·AIDS Research and Human Retroviruses ·Paul Coplan, Alexander Nikas, Anthony J. Japour, (unknown), Hilal Maradit Kremers, (unknown), Yi Xu, Mark J. DiNubile	50
3	Scientific and Ethical Considerations in Trial Design for Investigational Agents for the Treatment of Human Immunodeficiency Virus Infection 2003 ·Clinical Infectious Diseases ·Judith Feinberg, Anthony J. Japour	7
4	Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection breakdown → 2002 ·New England Journal of Medicine ·Sharon Walmsley, Barry Bernstein, Martin King, José Ramón Arribas, Gildon Beall, Peter Ruane, Margaret Johnson, David W. Johnson, Richard Lalonde, Anthony J. Japour, Scott Brun, Eugene Sun	518
5	Safety and Antiviral Activity at 48 Weeks of Lopinavir/Ritonavir plus Nevirapine and 2 Nucleoside Reverse‐Transcriptase Inhibitors in Human Immunodeficiency Virus Type 1–Infected Protease Inhibitor–Experienced Patients 2002 ·The Journal of Infectious Diseases ·Constance A. Benson, Steven G. Deeks, Scott C. Brun, Roy M. Gulick, Joseph J. Eron, Harold A. Kessler, Robert L. Murphy, Charles B. Hicks, Martin King, David A. Wheeler, Judith Feinberg, Richard Stryker, Paul E. Sax, Sharon A. Riddler, Melanie Thompson, (unknown), Ann Hsu, Dale J. Kempf, Anthony J. Japour, Eugene Sun	119
6	Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection 2001 ·AIDS ·Marc van der Valk, Elizabeth H. Gisolf, Peter Reiss, Ferdinand W.N.M. Wit, Anthony J. Japour, Gerrit Jan Weverling, S. A. Danner	132
7	ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results 2001 ·AIDS ·Robert L. Murphy, Scott Brun, Charles B. Hicks, Joseph J. Eron, Roy M. Gulick, Martin King, A. Clinton White, Constance A. Benson, Melanie Thompson, Harold A. Kessler, Scott Hammer, Richard Bertz, Ann Hsu, Anthony J. Japour, Eugene Sun	187
8	HIV-1 genotypic zidovudine drug resistance and the risk of maternal–infant transmission in the Women and Infants Transmission Study* 2000 ·AIDS ·(unknown), Jason J. Pitt, (unknown), Kenneth McIntosh, (unknown), Amy E. Colson, Shahin Lockman, Mary Glenn Fowler, Celine Hanson, Sheldon H. Landesman, Jack Moye, Kenneth Rich, C. Zorrilla, Anthony J. Japour	69
9	Changes in Virologic Markers as Predictors of CD4 Cell Decline and Progression of Disease in Human Immunodeficiency Virus Type 1‐Infected Adults Treated with Nucleosides 1998 ·The Journal of Infectious Diseases ·Susan A. Fiscus, Michael D. Hughes, Janet L. Lathey, (unknown), J. Brooks Jackson, Suraiya Rasheed, Tarek Elbeik, Richard C. Reichman, Anthony J. Japour, Roy Byington, (unknown), Brigitte P. Griffith, David Katzenstein, (unknown)	22
10	Variability and Prognostic Values of Virologic and CD4 Cell Measures in Human Immunodeficiency Virus Type 1‐Infected Patients with 200–500 CD4 Cells/mm³(ACTG 175) 1998 ·The Journal of Infectious Diseases ·Janet L. Lathey, Michael D. Hughes, Susan A. Fiscus, (unknown), J. Brooks Jackson, Suraiya Rasheed, Tarek Elbeik, Richard C. Reichman, Anthony J. Japour, Richard T. D’Aquila, (unknown), Brigitte P. Griffith, (unknown), David Katzenstein	38
11	Selective vertical transmission of HIV-1 antiretroviral resistance mutations 1998 ·AIDS ·Robert C. Colgrove, Jane Pitt, (unknown), Seth L. Welles, Anthony J. Japour	82
12	Insertions into the β3-β4 Hairpin Loop of HIV-1 Reverse Transcriptase Reveal a Role for Fingers Subdomain in Processive Polymerization 1998 ·Journal of Biological Chemistry ·Yvonne Kew, L.R. Olsen, Anthony J. Japour, Vinayaka R. Prasad	38
13	HIV protease inhibitors 1997 ·Current Opinion in Infectious Diseases ·Akhteruzzaman Molla, Anthony J. Japour	17
14	Prognostic Value of Plasma Human Immunodeficiency Virus Type 1 (HIV-l) RNA Levels in Patients with Advanced HIV-l Disease and with Little or No Prior Zidovudine Therapy 1996 ·The Journal of Infectious Diseases ·Seth L. Welles, J. Brooks Jackson, Belinda Yen‐Lieberman, Lisa M. Demeter, Anthony J. Japour, Laura Smeaton, Victoria A. Johnson, Daniel R. Kuritzkes, Richard T. D’Aquila, (unknown), Douglas D. Richman, Richard C. Reichman, Margaret A. Fischl, Raphael Dolin, Robert W. Coombs, James O. Kahn, C. McLaren, John A. Todd, Shirley Kwok, Clyde S. Crumpacker	74
15	The Relation of Virologic and Immunologic Markers to Clinical Outcomes after Nucleoside Therapy in HIV-Infected Adults with 200 to 500 CD4 Cells per Cubic Millimeter 1996 ·New England Journal of Medicine ·David Katzenstein, Scott M. Hammer, Michael D. Hughes, Holly Gundacker, J. Brooks Jackson, Susan A. Fiscus, Suraiya Rasheed, Tarek Elbeik, Richard C. Reichman, Anthony J. Japour, Thomas C. Merigan, Martin Hirsch	393
16	A Phase-I Study of the Safety, Pharmacokinetics, and Antiviral Activity of Combination Didanosine and Ribavirin in Patients with HIV-1 Disease 1996 ·Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology ·Anthony J. Japour, Juan J.L. Lertora, (unknown), Alejo Erice, James D. Connor, Brigitte P. Griffith, Pamela Clax, Jeanne Holden‐Wiltse, (unknown), (unknown), Elizabeth Cooney, Richard B. Pollard, Joseph Timpone, C. McLaren, (unknown), Kenneth Wood, (unknown), Yiannis Bassiakos	34
17	Determination of HIV-1 susceptibility to reverse transcriptase (RT) inhibitors by a quantitative cell-free RT assay 1996 ·Clinical and Diagnostic Virology ·(unknown), Anthony J. Japour, Frank Brewster, Richard A. Joseph, (unknown), (unknown), P A Chatis	2
18	Association of Plasma Human Immunodeficiency Virus Type 1 RNA Level withRisk of Clinical Progression in Patients with Advanced Infection 1996 ·The Journal of Infectious Diseases ·Robert W. Coombs, Seth L. Welles, Carol J. Hooper, (unknown), Richard T. D’Aquila, Anthony J. Japour, Daniel R. Kuritzkes, Douglas D. Richman, Shirley Kwok, John A. Todd, J. Brooks Jackson, Victor DeGruttola, Clyde S. Crumpacker, James S. Kahn	143
19	A rapid, direct test for zidovudine susceptibility in clinical isolates of human immunodeficiency virus type 1 (HIV-1) from infected children 1995 ·Clinical and Diagnostic Virology ·Yan Lan, Anthony J. Japour, Steven Kim, Seth L. Welles, Clyde S. Crumpacker, Ellen Cooper, (unknown), (unknown)	1
20	Prevalence and Clinical Significance of Zidovudine Resistance Mutations in Human Immunodeficiency Virus Isolated from Patients after Long-Term Zidovudine Treatment 1995 ·The Journal of Infectious Diseases ·Anthony J. Japour, Seth L. Welles, Richard T. D’Aquila, Victoria A. Johnson, Douglas D. Richman, Robert W. Coombs, Patricia Reichelderfer, James O. Kahn, Clyde S. Crumpacker, Daniel R. Kuritzkes	109

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact